Artiva Biotherapeutics, Inc. (ARTV)
ARTVNASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$4.06
-0.1620 (-3.84%) today
At the close, Nov 10, 4:00 PM ET. After hours $4.06 -0.05%
- Market cap
- $198.49m
- P/E
- –
- EPS, last 4 quarters
- $-2.98
- Dividend yield
- –
- Day range
- $4.04 to $4.22
- 52-week range
- $2.96 to $14.53
- Average volume
- 765.2k
- Previous close
- $4.22
Analysts
5 coveringHold1 buy, 4 hold, 0 sell
Targets a year out average $14.33, +253.0% from here
Earnings
next estimate $-0.5900Next report
Dec 2025
+3.5%
Mar 2026
-8.0%
Jun 2026
+1.6%
Sep 2026
-3.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$22.90m | -$21.93m | -$24.43m | -$26.89m |
| Net income | -$21.53m | -$20.77m | -$23.52m | -$25.00m |
News
8 latest- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals RTTNews · Oct 30, 2026
- Artiva Halts AlloNK Development, Cuts Workforce By 94%; Stock Down RTTNews · Oct 27, 2026
- Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?Zacks · Jul 8, 2026
- Artiva Biotherapeutics (ARTV) Price Target Increased by 60.00% to 27.74Fintel · May 14, 2026
- Artiva Biotherapeutics Prices $300 Mln Stock, Pre-Funded Warrants Offering; Shares Rise RTTNews · May 8, 2026
- Artiva Posts Wider FY25 Loss, Prepares For Key AlloNK Data In Refractory RA RTTNews · Mar 11, 2026
- Artiva Biotherapeutics Names Thad Huston CFO RTTNews · Feb 24, 2026
- After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance RTTNews · Dec 9, 2025
The company
Artiva is a clinical-stage biotechnology company that has focused on developing allogeneic natural killer (NK) cell therapies for autoimmune diseases. AlloNK (AB-101), the Company's lead development candidate, is a non-genetically modified, allogeneic, cryopreserved NK cell therapy that was evaluated in combination with B-cell-targeted monoclonal antibodies. Artiva is headquartered in San Diego, California.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- artivabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.